Skip to content

Efficacy and Safety of Ruxolitinib Cream in the Treatment of Ocular Vitiligo: A Single-Center, Real-World Study

Efficacy and Safety of Ruxolitinib Cream in the Treatment of Ocular Vitiligo: A Single-Center, Real-World Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124695
Enrollment
Unknown
Registered
2026-05-15
Start date
2026-05-15
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Interventions

Before and after comparison:Apply 1.5% lucotinin cream twice daily (BID). Dispense the study drug from the tube using a fingertip and apply it until all areas to be treated are covered with a thin lay

Sponsors

The Third Affiliated Hospital of Nanjing Medical University, Changzhou Second People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. All patients have been definitively diagnosed with non-segmental vitiligo and present with lesions on the eyelids; 2. Age > 12 years; 3. Routine tests indicate no abnormalities in liver or kidney function; 4. No concomitant eye diseases; intraocular pressure, fundus examination and slit-lamp examination reveal no abnormalities; 5. The patient consents to this treatment method.

Exclusion criteria

Exclusion criteria: 1. Patients belonging to special groups, such as those who are pregnant, breastfeeding, suffering from mental health conditions or concurrent eye diseases, and who are unable to comply with treatment; 2. patients with poor compliance who fail to take their medication regularly; 3. patients with infectious diseases such as syphilis, HIV/AIDS, hepatitis and tuberculosis; 4. patients with malignant tumours; 5. and patients with other serious systemic diseases.

Design outcomes

Primary

MeasureTime frame
Proportion of participants achieving F-VASI 75 at week 24;

Secondary

MeasureTime frame
F-VASI score;Local skin reaction;

Countries

China

Contacts

Public ContactCao Yan, Liu Xinyi

Changzhou Second People’s Hospital

czeycy2018@163.com+86 159 6142 6236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026